Vilnius, Lithuania, March 04, 2021 --(PR.com
)-- “Automation of radiology is no longer a promise - it is finally here. It combines our long-term research with firsthand feedback from medical institutions on how AI diagnostics can benefit daily medical practice. We are excited to be the pioneers in the autonomous AI diagnostics field and strongly believe autonomous products will finally boost AI clinical adoption,” notes CEO of Oxipit Gediminas Peksys.
The new AI application will only produce automated reports for chest X-rays, where it is highly confident that the images feature no abnormalities. This allows the sensitivity metric to be higher than 99%. The application is validated using a 500.000 X-ray dataset from multiple medical institutions where Oxipit AI products are currently deployed. Depending on the type of medical institution, the platform can autonomously report on up to 15% of the daily radiologist’s workflow.
“Initially this would be most helpful for primary care and diagnostics centers, where up to 80% of all chest X-rays feature no abnormalities. Furthermore, a similar autonomy framework can be adapted for large scale screening projects, such as the global tuberculosis effort,” adds Mr Peksys.
The new application builds upon the foundation of Oxipit ChestEye, an earlier Oxipit platform for preliminary chest X-ray reports. Oxipit ChestEye can identify 75 radiological findings - approx. 90% of abnormalities encountered by radiologists on a daily basis.
“Supporting this vast library of radiological findings enables us to rule out any pathologies with high confidence and achieve zero false negative cases across our pilot product deployment sites,” says Mr Peksys.